Prognostic factors in Barrett's esophagus: An immunohistochemical and morphometric study of 120 cases

Revista Espanola de Enfermedades Digestivas

Volumn 92, Issue 11, 2000, Pages 732-737

  Illueca Ballester, Carmen ^a,b   Llombart Bosch, A ^a   Ferrando Cucarella, J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b NONE   (Spain)

Author keywords

Adenocarcinoma; Barrett's esophagus; Dysplasia; p53 expression

Indexed keywords

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BARRETT ESOPHAGUS; ESOPHAGUS TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SEX DIFFERENCE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SEX FACTORS;

EID: 0041848284     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Barrett NR. Chronic peptic ulcer of the oesophagus and «oesophagitis». Br J Surg 1950;38:175-82.
2. Allison PR, Johnstone AS. The oesophagus lined with gastric mucous membrane. Thorax 1953;8:87-101.
3. Halvorsen JF, Semb BKH. The «Barrett syndrome» (the columnar-lined lower oesophagus): an acquired condition secondary to reflux oesophagitis. Acta Chir Scand 1975;141: 683-7.
4. Spechler SJ, Sperber H, Doos WG, Shimmel EM. The prevalence of Barrett's oesophagus in patients with chronic peptic oesophageal strictures. Dig Dis Sci 1983;28:769-74.
5. Raphael HA, Ellis FH, Dockerty MB. Primary adenocarcinoma of the oesophagus: 18-year review and review of literature. Ann Surg 1966;164:785-6.
6. Jernstrom P, Brewer LA. Primary adenocarcinoma in the mid-oesophagus arising in ectopic gastric mucosa with associated hiatal hiatal and reflux oesophagitis (Dowson's syndrome). Cancer 1970;26:1343-8.
7. Burns WA, Flores PA, Mosyedi A. Clinical conditions associated with columnar-lined oesophagus. Dig Dis 1970;15: 607-15.
8. Naef AP, Savary M, Ozello L. Columnar-lined lower oesophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's oesophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975;70: 826-35.
9. Spechler SJ, Robbins AH, Bloomfield RH, Vincent ME, Heeren T, Doos WG. Adenocarcinoma and Barrett's oesophagus. An overrated risk? Gastroenterology 1984;87: 927-33.
10. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's oesophagus). N. Engl J Med 1985;313:857-9.
11. Van der Veen AH, Dees J, Blankenstein JD, Van Blankenstein M. Adenocarcinoma in Barrett's oesophagus: an overrated risk. Gut 1989;30:14-8.
12. Paul A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett's oesophagus. N Engl J Med 1976;295:476-80.
13. Reid BJ, Haggitt RC, Rubin CE. Criteria for dysplasia in Barrett's oesophagus: a cooperative consensus study. Gastroenterology 1985;88:1552.
14. Cooper BT, Barbezat GO. Barrett's oesophagus: a clinical study of 52 patients. Q J Med 1987;238:98-108.
15. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's oesophagus. Am J Gastroenterol 1988;83:291-4.
16. Williamson WA, Ellis FH, Gibs SP, Shahian DM, Aretz HT, Heatley GJ. Barrett's oesophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151: 2212-6.
17. Cameron AJ. Epidemiology of columnar lined oesophagus and adenocarcinoma. Gastroenterol Clin North Am 1997; 26:487-94.
18. Griffin M, Sweeney EC. The relationship of endocrine cells, dysplasia and carcinoembryonic antigen in Barrett's mucosa to adenocarcinoma of oesophagus. Histopathology 1987;11:53-62.
19. Kim R, Clarke MR, Melhem MF, Young MA, Vanbibber MM, Safatle-Ribeiro AV, et al. Expression of p53, PCNA, and c-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997;42:2453-62.
20. Jankowski J, McMenemin R, Yu C, Hopwood D, Wormsley KG. Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. Gut 1992;33:587-91.
21. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
22. Peters FT, Ganesh S, Kuipers EJ, De Jager-Krikken A, Harms G, Sluiter WJ, et al. Epitelial cell proliferative activity of Barrett's oesophagus: methodology and correlation with traditional cancer risk markers. Dig Dis Sci 1998;43: 1501-6.
23. Jankowski J, Coghill G, Hopwood D, Wormsley KG. Onco-genes and onco-suppressor genes in adenocarcinoma of the oesophagus. Gut 1992;33:1033-8.
24. Fléjou J-F, Potet F, Muzeau F, Le Pelletier F, Fekete F, Henin D. Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol 1993;464: 330-3.
25. Symmans PJ, Linehan JM, Brito MJ, Filipe MI. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994;173:221-6.
26. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 disfunction in the dysplasia/carcinoma sequence. Gut 1994;35:764-8.
27. Younes M, Lebovitz RLM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. Gastroenterology 1993;105: 1637-42.
28. Krishnadath KK, Tilanus HW, Van Blankenstein M, Bosman FT, Mulder AH. Accumulation of p53 protein in normal, dysplasic, and neoplastic Barrett's oesophagus. J Pathol 1995;175:175-80.
29. Tsung-Teh Wu, Tashiaki Watanabe, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction region. Am J Pathol 1998;153: 287-94.
30. Moskaluk CA, Heitmiller R, Zahurak M, Schwab D, Sidransky D, Hamilton SR. P53 and p21 (WAF1/CIP1/SDI1) gene products in Barrett's oesophagus and adenocarcinoma of the oesophagus and oesophagogastric junction. Human Pathology 1996;27:1211-20.
31. Reid BJ, Haggitt RC, Rubin CE: Barrett's oesophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987;93:1-11.
32. Ortiz-Hidalgo C, De la Vega G, Aguirre-García J. The histopathology and biologic prognostic factors of Barrett's oesophagus: a review. J Clin Gastroenterol 1998;26:324-33.
33. Robaszkiewicz M, Hardy E, Volant A. Analyse du contenu cellulaire en ADN par cytometrie en flux dans les endobrachyoesophages. Etude de 66 cas. Gastroenterol Clin Biol 1991;15:703-10.
34. Menke-Pluymers MBE, Mulder AH, Hop WCJ, Van Blankenstein M, Tilanus HW. Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. Gut 1994;35:1348-51.
35. Giménez-Bascuñana A, Minguela Puras A, Bermejo López J, Sola-Pérez J, Álvarez-López R, García-Alonso AM. Determinación de la ploidía tisular mediante citometría de flujo de DNA y detección inmunohistoquímica de la proteína p53. Su relación con la displasia en el esófago de Barrett. Rev Esp Patol 1998;31:111-20.
36. Haggitt RC, Reid BJ, Rabinovitch PS. Barrett's oesophagus: correlation between mucin histochemistry, flow cytometry, and histologic diagnosis for predicting increased cancer risk. Am J Pathol 1988;131:53-61.
37. McKinley MJ, Budman DR, Grueneberg D. DNA content in Barrett's oesophagus and oesophageal malignancy. Am J Gastroenterol 1987;82:1012-5.
38. Ramel S, Reid BJ, Sánchez CA. Evaluation of p53 protein expression in Barrett's oesophagus by two-parameter flow cytometry. Gastroenterology. 1992;102:1220-8.
39. Reid BJ, Blount PL, Rubin CE. Flow-cytometric and histological progression to malignancy in Barrett's oesophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
40. Sciallero S, Giaretti W, Bonelli L. DNA content analysis of Barrett's oesophagus by flow cytometry. Endoscopy 1993; 25:648-51.
41. Ridell RH. Are there histological criteria that are capable of distinguishing high-grade dysplasia with biologic potential of invasion from high-grade dysplasia without invasive potential? En: Giulli et al, eds. The oesophageal mucosa. Amsterdam: Elsevier; 1994. p. 1004-8.
42. Ferrando I, Ferrando J, Reig G, Navarro P, Llombart-Bosch A, Mínguez M, Mora F, Benages A. Esófago de Barrett. Marcadores para diferenciar grupos de riesgo. Rev Esp Enferm Dig 1998;90:431-5.
43. Rabinovitch PS. Reid BJ, Haggitt RC, Norwood TH, Cyrus ER. Progression to cancer in Barrett's oesophagus is associated with genomic instability. Lab Invest 1988;60:65-71.
44. Polkowski W, Ba ik JP, van Lanschot JJ, Meijer GA, Schuurmans LT, Ten Kite FJ, et al. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation. J Pathol 1998; 184:161-8.